Working with many rare forms of blood disorders, the Stanford Hematology Program brings together a multispecialty team of experts dedicated to treating leukemia as well as other benign and malignant hematologic disorders.
Through their laboratory investigation and clinical research, Stanford clinicians are identifying the biologic mechanisms responsible for the development of leukemia, and developing more effective therapies to address these diseases. For example, researchers recently identified a set of 133 genes that point to the most dangerous strains of adult acute myeloid leukemia or AML. In the not so distant future, their research may help doctors pick the best treatment for their AML patients.
With expertise in the basic and clinical sciences, Stanford investigators are delving into the basic origins of blood diseases and in turn translating their findings into the most advanced diagnostic and treatment strategies available today.
As an academic medical institution, the Stanford Cancer Center is committed to improving the standard of care for the millions of individuals worldwide who receive a cancer diagnosis each year. Drawing upon the expertise of more than 240 researchers and clinicians from the Schools of Medicine, Engineering and Humanities & Sciences, the center is at the forefront of today's advances in cancer research and medicine.
Eligibility Flowcharts for Blood Diseases/Hematology
Robert Negrin, MD, Director of Stanford's Blood and Marrow Transplant program on why he left biochemistry to become a hematologist.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.